COVID-19 Vaccine's mRNA Technology Adapted for First Antibiotic-Resistant Bacteria Vaccine
Researchers have created the world's first mRNA-based vaccine against a deadly, antibiotic-resistant bacterium — and they did it using the platform developed for COVID-19 vaccines. Medical Express publishes their announcement: The vaccine developed by the team from the Institute for Biological Research and Tel Aviv University is an mRNA-based vaccine delivered via lipid nanoparticles, similar to the COVID-19 vaccine. However, mRNA vaccines are typically effective against viruses like COVID-19 — not against bacteria like the plague... In 2023, the researchers developed a unique method for producing the bacterial protein within a human cell in a way that prompts the immune system to recognize it as a genuine bacterial protein and thus learn to defend against it. The researchers from Tel Aviv University and the Institute for Biological Research proved, for the first time, that it is possible to develop an effective mRNA vaccine against bacteria. They chose Yersinia pestis, the bacterium that causes bubonic plague — a disease responsible for deadly pandemics throughout human history. In animal models, the researchers demonstrated that it is possible to effectively vaccinate against the disease with a single dose. The team of researchers was led by Professor Dan Peer at Tel Aviv University, a global pioneer in mRNA drug development, who says the success of the current study now "paves the way for a whole world of mRNA-based vaccines against other deadly bacteria."

Read more of this story at Slashdot.